What is Survodutide?
Survodutide is a synthetic 34-amino-acid peptide that acts as a dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide-1 (GLP-1) receptor. Unlike oxyntomodulin-derived dual agonists, survodutide is built on the native glucagon sequence and modified with amino-acid substitutions that add GLP-1 receptor activity, plus a fatty diacid side chain that binds albumin for a once-weekly profile in published studies.
Survodutide, also known by its development code BI 456906, is an investigational compound in late-stage clinical trials and has not been licensed as a medicine. GenoPept supplies survodutide as a research peptide for UK laboratories studying glucagon-centred dual agonism. It is for in-vitro research use only.
Survodutide research applications
Survodutide is of particular interest because of its relatively strong glucagon receptor component. The preclinical research areas below are the most common.
Glucagon receptor biology
Survodutide is used in receptor signalling assays to characterise the balance between glucagon and GLP-1 receptor activation and to study how glucagon receptor engagement affects hepatocyte cAMP signalling and gene expression.
Fatty liver and steatohepatitis models
A major research focus is hepatic fat. Survodutide has been investigated in rodent models of steatohepatitis, measuring liver triglycerides, lipid oxidation, inflammatory markers and fibrosis, since glucagon receptor activation directly drives hepatic lipid catabolism.
Energy expenditure and body composition
Diet-induced obesity models are used to examine the compound’s effects on food intake, energy expenditure and fat mass, with comparisons against selective GLP-1 receptor agonists to quantify the glucagon contribution.
Glucose homeostasis
Research explores whether the GLP-1 receptor activity of survodutide is sufficient to counterbalance glucagon-driven hepatic glucose output, using glucose tolerance tests and islet hormone measurements in animal models.
Mechanism of action (preclinical)
Survodutide activates two class B G-protein-coupled receptors. At the glucagon receptor it stimulates hepatic cAMP signalling, increasing fatty acid oxidation, ketogenesis and glycogenolysis, and in adipose tissue it promotes lipolysis and energy expenditure.
At the GLP-1 receptor survodutide enhances glucose-dependent insulin secretion, slows gastric emptying and reduces food intake through central pathways. In preclinical models the two actions are reported to combine so that body weight and liver fat fall while glucose control is maintained, an effect attributed to the GLP-1 component offsetting glucagon’s glucose-raising action.
Survodutide product specifications
| Specification | Detail |
|---|---|
| Compound | Survodutide |
| Also known as | BI 456906, BI456906, glucagon/GLP-1 dual receptor agonist, survodutide acetate |
| Sequence / class | 34-amino-acid synthetic glucagon-based peptide with a fatty diacid side chain, engineered for dual GLP-1 and glucagon receptor agonism |
| CAS number | 2805997-46-8 |
| Molecular formula | C192H289N47O61 |
| Molecular weight | 4231.7 g/mol |
| Form | Lyophilised (freeze-dried) powder in a sealed sterile glass vial, black cap, lot and expiry on label |
| Available sizes | 5mg, 10mg |
| Purity | ≥99% (HPLC) |
| Verification | Batch HPLC purity and LC-MS identity testing by an independent ISO/IEC 17025 laboratory (Puralytix), with Certificate of Analysis |
| Storage (unopened) | −20 °C long term; 2–8 °C short term; protect from light |
| Intended use | In-vitro laboratory research only. Not for human or veterinary use |
Available sizes
Survodutide is available in the following vial sizes:
- 5mg vial
- 10mg vial
Laboratories that need larger quantities can order in bulk boxes of 10 vials, which save 20–50% against single-vial pricing. Retail baskets also receive automatic discounts at £300, £500 and £1,000, and delivery is free on UK orders of £200 or more.
Reconstitution, handling and storage (laboratory)
Unopened Survodutide vials should be stored at −20 °C for long-term storage, or at 2–8 °C for short periods, and protected from light. Allow the vial to reach room temperature before opening to avoid condensation on the lyophilised cake.
To reconstitute for in-vitro work, add bacteriostatic water or another sterile diluent slowly down the inside wall of the vial, then swirl gently until the powder dissolves. Do not shake, as agitation can damage large acylated peptides. Reconstituted solution should be kept at 2–8 °C and used within the period specified in the laboratory’s own protocol. See our guides on how to reconstitute research peptides and how to store research peptides for step-by-step handling notes.
Quality assurance and Certificate of Analysis
Every batch of Survodutide is tested by an independent third-party laboratory (Puralytix, ISO/IEC 17025 accredited) using HPLC for purity and LC-MS for identity confirmation. Results are published in a batch-specific Certificate of Analysis (COA), and each vial is labelled with its lot number and expiry date so the paperwork can be matched to the product on the bench.
Use the “View Certificate of Analysis” button on this page to open the current batch COA, or browse the full COA library. Our article on what a Certificate of Analysis shows explains how to read the chromatogram and mass spectrum.
Related research compounds
- Mazdutide: an oxyntomodulin-based GLP-1/glucagon dual agonist for scaffold comparison.
- Retatrutide: a triple agonist that adds GIP receptor activity.
- Semaglutide: the selective GLP-1 receptor agonist control for glucagon-contribution studies.
- 5-Amino-1MQ: a small-molecule NNMT inhibitor studied in adipocyte metabolism.
Survodutide frequently asked questions
What is survodutide used for in research?
Survodutide is used in laboratories as a glucagon-based dual GLP-1 and glucagon receptor agonist. Preclinical research applies it to receptor signalling studies, fatty liver and steatohepatitis models, diet-induced obesity and energy expenditure experiments, and glucose homeostasis work. It is supplied for these in-vitro and animal-model research uses only and not for human or veterinary use.
How is survodutide supplied and what purity can I expect?
It is supplied as lyophilised powder in a sealed sterile glass vial with a black cap, labelled with lot number and expiry date. Each batch is verified by an independent ISO/IEC 17025 laboratory using HPLC for purity of at least 99% and LC-MS for identity, with the Certificate of Analysis available on the product page.
How should survodutide be stored?
Keep unopened vials at minus 20 degrees Celsius for long-term storage, or at 2 to 8 degrees Celsius for short periods, and protect them from light. After reconstitution with bacteriostatic water or sterile diluent, store the solution at 2 to 8 degrees Celsius and use it within the timeframe defined in your laboratory protocol.
Is survodutide from GenoPept for human use?
No. This product is supplied by GenoPept strictly for in-vitro laboratory research. It is an investigational compound, not a licensed medicine, and must not be used for human or veterinary purposes, diagnosis or treatment. Purchasers are responsible for complying with UK research use only requirements and their own institutional safety policies.
How does survodutide compare with retatrutide?
Survodutide is a dual agonist of the glucagon and GLP-1 receptors, while retatrutide is a triple agonist that also activates the GIP receptor. Survodutide is a shorter 34-amino-acid glucagon-derived peptide, whereas retatrutide is a 39-amino-acid GIP-derived sequence. Researchers use the pair to isolate the incremental effect of GIP receptor activation in metabolic models.
Research use only. Survodutide is supplied by GenoPept strictly for in-vitro laboratory research. It is not a medicine, is not for human or veterinary use, and is not intended for diagnostic or therapeutic purposes. Read our research use only policy and UK legal guide before ordering.
Reviews
There are no reviews yet.